Literature DB >> 12114729

TGF-B and Estrogen Regulate P27(Kip1) and Cyclin D(1) in Normal and Neoplastic Rat Pituitary Cells.

Xiang Qian1, Long Jin, Ricardo V. Lloyd.   

Abstract

Pituitary hyperplasia and tumor growth are regulated by various hormones and growth factors. Estrogen (E(2)) stimulates pituitary cell proliferation and prolactin (PRL) production. Estrogen also regulates transforming growth factor-B (TGF-B) effects in the pituitary. IGF-B in turn regulates various cell cycle proteins including p15 and p27(Kip1) (p27). To better understand the regulatory role of growth factors and hormones in the cell cycle we analyzed cyclin D(1), cyclin E, and p27 expression in normal and neoplastic rat pituitary cells. An in vitro analysis using cultured normal pituitary cells and GH(3) tumor cells and an in vivo analysis of estrogen-treated normal pituitary and implanted GH(3) cells were performed. Semiquantitative RT-PCR was used to analyze mRNA expression for cyclin D(1) cyclin E, and p27 in cultured pituitary cells and E(2)-treated pituitaries in vivo, Cyclin D(1) and p27 were localized in the nuclei of normal pituitary cells by immunocytochemistry (ICC). Very weak or absent immunostaining for cyclin D(1) and p27 was present in GH(3) cells. Both normal pituitary and GH(3) cells had strong nuclear staining for cyclin E. Normal pituitary had a 20-fold greater amount of cyclin D mRNA and a 3-fold greater amount of p27 mRNA compared to GH cells, whereas GH cells had slightly (1.5-fold) more cyclin E than normal pituitary cells. Treatment in vivo stimulated cell proliferation and decreased cyclin D(1) mRNA levels in normal pituitary. GH(3) tumor cells, implanted subcutaneously in the same animal, showed increased proliferation after E(2) treatment, but there was no change in cyclin B(1) mRNA in GH(3) cells. Cyclin E and p27 mRNA levels did not change significantly in normal pituitary or in GH(3) cells after E(2) treatment in vivo. Treatment of normal pituitary cells with 10(-9)M TGF-B1 for 3 d in vitro led to significant decreases in cyclin B(1) and p27 mRNAs (p < 0.05 ), whereas cyclin E levels were unchanged. These results indicate that cyclin B(1) and p27 mRNAs are present at significantly higher levels in normal pituitary compared to GH(3) cells, and that both E(2) and TGF-B1 can down-regulate cyclin B(1) mRNA levels in normal pituitary cells, suggesting that these factors regulate G1 to S phase transition in pituitary cells. The lower levels of specific cell cycle regulators in GH cells may explain the decreased regulatory control by E(2) in GH(3) tumor cells.

Entities:  

Year:  1997        PMID: 12114729     DOI: 10.1007/bf02738792

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  40 in total

1.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

2.  Transforming growth factor beta and cell cycle regulation.

Authors:  M G Alexandrow; H L Moses
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701

3.  Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.

Authors:  K Nakayama; N Ishida; M Shirane; A Inomata; T Inoue; N Shishido; I Horii; D Y Loh; K Nakayama
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

4.  Transforming growth factor beta 1-like immunoreactivity in the pituitary gland of the rat: effect of estrogen.

Authors:  G Burns; D K Sarkar
Journal:  Endocrinology       Date:  1993-09       Impact factor: 4.736

5.  Cyclin G: a new mammalian cyclin with homology to fission yeast Cig1.

Authors:  K Tamura; Y Kanaoka; S Jinno; A Nagata; Y Ogiso; K Shimizu; T Hayakawa; H Nojima; H Okayama
Journal:  Oncogene       Date:  1993-08       Impact factor: 9.867

6.  Analysis of prolactin and growth hormone production in hyperplastic and neoplastic rat pituitary tissues by the hemolytic plaque assay.

Authors:  R V Lloyd; K Coleman; K Fields; V Nath
Journal:  Cancer Res       Date:  1987-02-15       Impact factor: 12.701

7.  Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta.

Authors:  A Koff; M Ohtsuki; K Polyak; J M Roberts; J Massagué
Journal:  Science       Date:  1993-04-23       Impact factor: 47.728

8.  Expression and Regulation of Transforming Growth Factor B1 in Cultured Normal and Neoplastic Rat Pituitary Cells.

Authors:  Xiang Qian; Long Jin; Ricardo V. Lloyd
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

9.  Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family.

Authors:  A Koff; F Cross; A Fisher; J Schumacher; K Leguellec; M Philippe; J M Roberts
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

10.  Human cyclin D1 encodes a labile nuclear protein whose synthesis is directly induced by growth factors and suppressed by cyclic AMP.

Authors:  A Sewing; C Bürger; S Brüsselbach; C Schalk; F C Lucibello; R Müller
Journal:  J Cell Sci       Date:  1993-02       Impact factor: 5.285

View more
  3 in total

Review 1.  Aspects of anterior pituitary growth, with special reference to corticotrophs.

Authors:  A M McNicol; E Carbajo-Perez
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

2.  Estrogen downregulates neuronal nitric oxide synthase in rat anterior pituitary cells and GH3 tumors.

Authors:  X Qian; L Jin; R V Lloyd
Journal:  Endocrine       Date:  1999-10       Impact factor: 3.633

3.  Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors.

Authors:  Katja Kiseljak-Vassiliades; Mei Xu; Taylor S Mills; Elizabeth E Smith; Lori J Silveira; Kevin O Lillehei; Janice M Kerr; B K Kleinschmidt-DeMasters; Margaret E Wierman
Journal:  Mol Cell Endocrinol       Date:  2015-09-21       Impact factor: 4.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.